Cordis/Advanced Cell Technology
This article was originally published in The Gray Sheet
Executive Summary
The Biologics Delivery Systems group of Johnson & Johnson/Cordis will supply catheters for administering Advanced Cell Technology's stem cell therapy for treatment of heart failure in a Phase II clinical trial, ACT announces March 5. The myoblast therapy involves transplanting stem cells derived from a patient's leg muscle into scarred heart tissue to help rebuild the heart muscle and prevent progression of congestive heart failure. The trial will use the Cordis group's NOGA cardiac navigation system and MyoStar injection catheter. Medtronic and Genzyme are also collaborating on catheter delivery of myoblast treatment (1"The Gray Sheet" June 7, 2004, p. 13)
You may also be interested in...
Medtronic Gets To Heart Of Cell Therapy Through Genzyme Collaboration
Medtronic will draw on expertise from its three cardiac-related divisions to aid Genzyme in the development of a catheter-delivered cell therapy for cardiovascular disease
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.